Vegan diet, processed foods, and body weight: a secondary analysis of a randomized clinical trial
Abstract
Low-fat plant-based diets cause weight loss in clinical trials. However, many foods are highly processed, raising the question as to their effect on body weight. This secondary analysis assessed the associations between changes in processed food intake and weight loss in 244 overweight adults randomly assigned to a vegan (n = 122) or control group (n = 122) for 16 weeks. Three-day dietary records were analyzed using the NOVA system, which categorizes foods from 1 to 4, based on degree of processing. A repeated measure ANOVA, Pearson correlations, and a multivariate regression model were used for statistical analysis. The consumption of animal foods in categories 1–4 decreased in the vegan group, compared with the control group. Body weight decreased in the vegan group (treatment effect − 5.9 kg [95% CI -6.7 to -5.0]; Gxt, p < 0.001). Changes in consumption of animal foods in categories 1–4 were positively associated with changes in body weight: r = + 0.34; p < 0.001 for category 1; r = + 0.18; p = 0.008 for category 2; r = + 0.17; p = 0.01 for category 3; and r = + 0.22; p = 0.001 for category 4. In no NOVA category was the consumption of plant-based processed foods positively and significantly associated with weight gain. The top three independent predictors of weight loss were reduced intakes of processed, unprocessed or minimally processed, and ultra-processed animal foods. These findings suggest that replacing animal products with plant-based foods may be an effective…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 244 participants or records.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.